InsidersTradesSigma
Follow the Tricida, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Tricida, Inc. has published 63 insider filings. The latest transaction was filed on 25 November 2022 (Cession). Among the most active insiders: Venrock Healthcare Capital Partners II, L.P.. The full history is openly available.
63
Insider Decl.
n/a
Thresholds
€19m
19 ops.
Buy Volume
€5m
28 ops.
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 November 2022
Declarations63 total
131,879 shares@ US$0.2181.4% of flowCommon StockSEC:0001595585-22-000093:0
1,034,421 shares@ US$0.223.1% of flowCommon StockSEC:0000947871-22-001207:0
1,034,421 shares@ US$0.223.1% of flowCommon StockSEC:0000947871-22-001208:0
27,584 shares@ US$0.2318.6% of flowCommon StockSEC:0001595585-22-000091:0
2,113,948 shares@ US$0.616.6% of flowCommon StockSEC:0001209191-22-054671:0
40,400 shares@ US$11.982.5% of flowCommon StockSEC:0001209191-22-054201:0
Canonical exit: 16 Jan 2023 (T+90)
4,674 shares@ US$11.980.3% of flowCommon StockSEC:0001209191-22-053863:0
Canonical exit: 11 Jan 2023 (T+90)
95,366 shares@ US$12.0166.8% of flowCommon StockSEC:0001446472-22-000002:0
28,900 shares@ US$12.001.8% of flowCommon StockSEC:0001209191-22-053374:0
Canonical exit: 5 Jan 2023 (T+90)
223,100 shares@ US$11.8113.3% of flowCommon StockSEC:0001209191-22-052991:0
Canonical exit: 2 Jan 2023 (T+90)
14,995 shares@ US$10.679.2% of flowCommon StockSEC:0001744981-22-000004:0
168,187 shares@ US$9.928.6% of flowCommon StockSEC:0001209191-22-051925:0
Canonical exit: 28 Dec 2022 (T+90)
395,614 shares@ US$8.5617.8% of flowCommon StockSEC:0001209191-22-051501:0
Canonical exit: 25 Dec 2022 (T+90)
63,030 shares@ US$12.764.1% of flowCommon StockSEC:0001209191-22-048998:0
Canonical exit: 1 Dec 2022 (T+90)
50,000 shares@ US$12.203.1% of flowCommon StockSEC:0001209191-22-048246:0
Canonical exit: 28 Nov 2022 (T+90)
32,220 shares@ US$13.5023.9% of flowCommon StockSEC:0001744981-22-000003:0
18,900 shares@ US$9.210.9% of flowCommon StockSEC:0001209191-22-043953:0
Canonical exit: 27 Oct 2022 (T+90)
30,000 shares@ US$9.591.4% of flowCommon StockSEC:0001209191-22-043141:0
Canonical exit: 19 Oct 2022 (T+90)
100,000 shares@ US$9.024.5% of flowCommon StockSEC:0001209191-22-042695:0
Canonical exit: 16 Oct 2022 (T+90)
25,000 shares@ US$9.811.2% of flowCommon StockSEC:0001209191-22-042154:0
Canonical exit: 10 Oct 2022 (T+90)
55,700 shares@ US$9.652.6% of flowCommon StockSEC:0001209191-22-041196:0
Canonical exit: 29 Sept 2022 (T+90)
34,366 shares@ US$9.715.1% of flowCommon StockSEC:0001209191-22-039936:0
Canonical exit: 26 Sept 2022 (T+90)
142,900 shares@ US$10.9023.6% of flowCommon StockSEC:0001209191-22-039309:0
Canonical exit: 20 Sept 2022 (T+90)
5,951 shares@ US$9.690.9% of flowCommon StockSEC:0001209191-22-038479:0
Canonical exit: 14 Sept 2022 (T+90)
58,054 shares@ US$8.917.8% of flowCommon StockSEC:0001209191-22-036738:0
Canonical exit: 8 Sept 2022 (T+90)
25 of 63 declarations
关于 Tricida, Inc.
Tricida, Inc.是一家美国生物制药公司，历来在美国纳斯达克市场上市，具体为纳斯达克全球精选市场，股票代码为TCDA，后因重组诉讼相关的退市轨迹而被摘牌。该公司成立于2013年，在特拉华州注册成立，在加州建立了运营足迹，主要办公室位于南旧金山。Tricida的商业模式围绕单一主要开发资产veverimer（也称为TRC101）展开，这是一种口服给药、非吸收聚合物，设计用于治疗慢性肾脏病（CKD）患者的代谢性酸中毒。换句话说，Tricida主要是一家药物开发公司，而非多元化的商业制药集团，其企业价值与一个主要候选药物的临床、监管和融资进展相关联。这种专注战略为公司提供了明确的治疗学论点，但也集中了风险：投资案例在很大程度上取决于监管认可、试验结果和公司获得足够资金以达到商业化的能力。从竞争角度来看，Tricida在专业肾脏/代谢领域运营，与更广泛的CKD支持疗法和其他医学方法间接竞争，同时缺乏大型制药公司的产品广度、国际规模和商业基础设施。最近的企业历史主要由财务困境和重组主导。Tricida于2023年1月11日申请了第11章破产保护，随后披露了计划向SEC注销其证券并暂停报告义务。对于投资者，特别是那些追踪SEC表格4内部人士活动的投资者，TCDA是一个单一资产生物技术公司的例子，具有高风险、二元性质：一方面是有前景的科学专注，但另一方面存在临床不确定性、监管挫折、流动性压力、稀释和最终丧失交易所交易相关性的重大敞口。鉴于其美国市场上市和纳斯达克历史，对Tricida的任何分析都应通过美国公开市场和后期生物技术开发资本密集现实的视角来框架化。
